Genetown
Filter News
Found 72,171 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
BioSpace Movers & Shakers, June 18
6/18/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
6/18/2021
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation.
-
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
6/18/2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® (zanubrutinib) has received conditional approval from the China National Medical Products Administration
-
Moderna Reaffirms Commitment to Job Creation in Massachusetts
6/18/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reaffirmed its commitment to job creation in Massachusetts.
-
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress
6/18/2021
Scholar Rock today announced an oral e-presentation of clinical results from the TOPAZ Phase 2 trial.
-
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment
6/18/2021
Jacobio Pharmaceuticals has announced that the first two patients have been dosed in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively, thereby triggering the US$20 million milestone payment from AbbVie.
-
Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum
6/18/2021
Entasis Therapeutics Holdings Inc. today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24.
-
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
6/18/2021
Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral research related to Brilacidin has been accepted for an Oral Presentation at the 2021 Military Health System Research Symposium (MHSRS),
-
The U.S. FDA approved Ayvakit for the treatment of adult patients with advanced sytematic mastocytosis (SM), advanced SM, and mast cell leukemia.
-
XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody designed to improve upon the safety of current therapies in the same class.
-
Cyteir Therapeutics Announces Pricing of Initial Public Offering
6/17/2021
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share
-
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
6/17/2021
Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been dosed in the global clinical study, TOPAZ-1.
-
Verve Therapeutics Announces Pricing of Initial Public Offering
6/17/2021
Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share
-
Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials
6/17/2021
Anji Pharma announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the program's MCL1 inhibitors.
-
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
6/17/2021
Agenus Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted Agenus’ Biologics License Application (BLA) for balstilimab.
-
Hologic Completes Acquisition of Mobidiag
6/17/2021
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.
-
Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union
6/17/2021
Entera Bio Ltd. today announced the European Patent Office has granted a patent titled “Methods and Compositions for Oral Administration of Proteins”